Silo Pharma Inc. is focused on developing innovative therapeutics that leverage both traditional and psychedelic formulations to address a range of underserved medical conditions, including PTSD, chronic pain, and central nervous system diseases. The company employs a strategic approach by acquiring and licensing intellectual property from leading academic institutions and researchers, which allows them to create novel therapies. Silo Pharma is particularly interested in utilizing the 505(b)(2) regulatory pathway, which is designed to streamline the approval process for new drugs, thereby reducing costs and expediting access to treatments for patients with limited options.

The company is actively developing a pipeline of therapeutics, including drug SPC-15, which targets stress-induced affective disorders. This drug is designed to predict responses to pharmacological treatments through the use of metabolomic biomarkers and is delivered via a liquid nasal formulation. Silo Pharma's collaborations with prestigious research institutions, such as Columbia University, enhance their ability to innovate and address significant health challenges, particularly in populations at high risk for PTSD, such as military personnel and first responders. Their commitment to following scientific evidence ensures that they are targeting the most pressing medical needs with their therapeutic developments.

United States

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders.

Silo Pharma

Company Details